Stanford Radiation Oncology

What Stanford Radiation Oncology does

Stanford Radiation Oncology is a clinical and research department within Stanford University School of Medicine that delivers radiation therapy to approximately 2,000 new patients annually across its Palo Alto campus, South Bay (San Jose) satellite, and Turlock location. Its service offering spans conventional linear accelerator-based radiotherapy, stereotactic body and cranial radiosurgery, image-guided and intensity-modulated radiotherapy, proton therapy (including Mevion's ultra-compact proton system), brachytherapy (including 3D-printed applicators), and biology-guided radiotherapy on RefleXion X1. The department operates as part of a major academic medical center, with revenue generated through clinical billing for professional and technical radiation oncology services, NIH/NCI and industry-sponsored research grants, and partnerships with medical device manufacturers and other academic institutions.

The department's technology base is built on a continuously refreshed fleet of advanced treatment platforms (CyberKnife S7, RefleXion X1, AVATAR, Vita Linac, Mevion ultra-compact proton) integrated with image-guided and AI-assisted planning systems. Artificial intelligence is applied to image registration, auto-segmentation, treatment planning optimization, predictive analytics (including liquid biopsy models), clinical workflow automation, and recommendation engines. Faculty lead a substantial peer-reviewed publication and clinical trial portfolio, and the department maintains research alliances with Mevion, Leo Cancer Care, RefleXion, UCLA Health, and the Help Ukraine Group.

The business model is that of a fee-for-service academic clinical department, with revenue derived from professional and technical radiation oncology billing to patients and third-party payers, supplemented by extramural research funding and industry partnerships. Reimbursement is anchored to CPT-coded treatment delivery, with case mix skewed toward complex, high-acuity modalities such as proton therapy, SBRT, SRS, and image-guided IMRT. There is no direct product revenue; the department is a consumer, not a vendor, of most of the software and hardware platforms it deploys.

Name

Stanford Radiation Oncology

Legal name

Stanford University School of Medicine - Department of Radiation Oncology

Website

https://radonc.stanford.edu

Company type

Private

Founded year

1885

Operating status

Operating

Headcount range

11–50 employees

Short description

Stanford Radiation Oncology is the radiation therapy department of Stanford University School of Medicine, treating approximately 2,000 new patients annually across Palo Alto, South Bay, and Turlock with advanced modalities including proton therapy, CyberKnife, and biology-guided radiotherapy.

Ownership category

akta.pro rank

Product category

Radiation Oncology Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Hospitals (8060)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH), Radiation Dose Management & Analytics (HLACALAH), Medical Oncology (HLAKAFAB), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

Keywords

• Radiation oncology services
• Proton therapy treatment
• Stereotactic radiosurgery
• Cancer treatment center
• Radiation therapy research

Headquarters

HQ city

Stanford (Palo Alto)

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Patient Care Services: Revenue generated from providing radiation oncology treatment services to cancer patients. Services include external beam radiation therapy, proton therapy, brachytherapy, stereotactic radiosurgery, and other specialized radiation treatments. The department operates as part of Stanford Health Care, a nonprofit academic healthcare system.
2. Clinical Research and Trials: Grant funding and sponsored research revenue from NCI-designated cancer center programs, NIH grants, and industry collaborations for developing novel radiation therapies and cancer treatments.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Stanford Radiation Oncology is a clinical department within Stanford University School of Medicine that delivers advanced radiation therapy to cancer patients. Services include external beam radiation therapy (IMRT, VMAT), proton therapy (including the world's first ultra-compact proton system), stereotactic radiosurgery and SBRT, biology-guided radiotherapy on the RefleXion X1 platform, CyberKnife S7, brachytherapy, and total skin electron therapy. The department also operates ACGME-accredited residency programs, a CAMPEP-accredited medical physics residency, and a joint Biomedical Physics PhD program, while conducting NIH- and industry-funded clinical and translational research.

Differentiator

Problem solved

Functional benefit

Products and services

• External Beam Radiation Therapy (IMRT/VMAT) Intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) delivered on linear accelerators for precise dose delivery to tumors while sparing healthy tissue. Indicated for solid tumors of the brain, head and neck, breast, lung, prostate, gastrointestinal tract, and other sites; available to adult and pediatric cancer patients referred to Stanford Radiation Oncology.
• Ultra-compact Proton Therapy Proton beam therapy delivered using the world's first ultra-compact proton therapy system that fits in a standard treatment vault and supports upright patient positioning (via Leo Cancer Care). Indicated for pediatric and adult patients with cancers where precise proton delivery minimizes healthy-tissue damage, including brain tumors and other malignancies.
• RefleXion X1 Biology-Guided Radiotherapy Biology-guided radiotherapy delivered on the RefleXion X1 platform, which fuses a 6MV linear accelerator with PET imaging for real-time tumor tracking during SBRT, SRS, and IMRT delivery. Indicated for cancer patients who would benefit from real-time biology-guided tumor targeting; available as part of Stanford's research and clinical program.
• CyberKnife S7 Stereotactic Radiosurgery Robotic stereotactic radiosurgery delivered with the CyberKnife S7 at the Stanford Neurosciences Health Center for precise, non-invasive treatment of intracranial and extracranial lesions. Indicated for patients requiring frameless stereotactic radiosurgery for brain, spine, and other targets.
• Total Skin Electron Therapy Stanford-developed Total Skin Radiation Technique using scattered electrons to treat broad cutaneous surfaces for cutaneous T-cell lymphoma and other skin-involving malignancies. Indicated for patients with extensive skin lymphoma involvement requiring whole-skin field irradiation.
• FLASH Radiotherapy (Investigational) Ultra-high dose rate (FLASH) radiotherapy delivered in under a second, studied at Stanford for its potential to improve tumor specificity and reduce normal-tissue toxicity. Indicated for eligible cancer patients enrolled in research protocols investigating this next-generation treatment modality.
• Radiation Oncology Therapy Residency Program Four-year ACGME-accredited residency program in radiation oncology, led by Program Director Hilary Bagshaw and Associate Program Director Michael Binkley. Indicated for medical school graduates seeking specialty training in radiation oncology, with ACGME accreditation continuation confirmed as of March 1, 2022.
• Medical Physics Residency Program Two-year CAMPEP-accredited residency in medical physics, led by Program Director Amy Shu-Jung Yu and Associate Director Yu Gao. Indicated for graduates of CAMPEP-accredited medical physics programs seeking clinical residency training.
• Biomedical Physics (BMP) PhD Program Doctoral training program in biomedical physics launched in 2021 as a joint program by the Departments of Radiology and Radiation Oncology. Indicated for graduate students pursuing PhD-level research training, with approximately 50 faculty mentors available across the two departments.
• Medical Student Clerkship in Radiation Oncology Clerkship and elective rotations for third- and fourth-year medical students seeking exposure to radiation oncology, directed by Elham Rahimy. Indicated for Stanford medical students and visiting students seeking hands-on training in advanced radiation therapy technology.

Quantifiable outcome

• Hodgkin's lymphoma is now one of the most treatable and curable forms of cancer thanks to Stanford treatment protocols
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• Mevion Medical SystemscoreTechnology or Integration · 7 April 2026Collaboration with Mevion to develop the world's first ultra-compact proton therapy system that reduces the footprint from the size of a football field to a standard treatment vault. Stanford helped innovate ways to shrink proton therapy technology, making it more accessible for cancer centers.
• Leo Cancer CarecoreTechnology or Integration · 7 April 2026Partnership with Leo Cancer Care, which is changing the paradigm of conventional patient imaging for proton therapy delivery. Their technology enables innovative upright patient positioning during treatment.
• UCLA HealthmajorStrategic or Co-development Partner · 27 March 2026Collaboration led by Dr. Anusha Kalbasi at Stanford Medicine in partnership with UCLA Health published research in Cancer Discovery on triple-threat combination of radiation and immunotherapy for sarcoma treatment.
• Help Ukraine Group (HUG)majorStrategic or Co-development Partner · 24 February 2022International group of 12 oncology practitioners co-founded by Dr. Nataliya Kovalchuk to support Ukrainian cancer centers. Stanford Healthcare donated over $415,000 worth of medical supplies. The initiative supports Ukraine's transition from Cobalt-60 to IMRT through comprehensive training programs.
• RefleXioncoreTechnology or Integration · 6 August 2021Stanford is the first radiation oncology program in the world to test the biology-guided radiotherapy platform known as RefleXion X1. The FDA-cleared machine combines a 6MV linear accelerator with PET technology for real-time tumor tracking.
• Union for International Cancer ControlminorStrategic or Co-development PartnerFunding secured together with Global Medical Knowledge Alliance to help train Ukrainian oncology practitioners as part of HUG initiative.
• TeleHelp UkraineminorStrategic or Co-development PartnerStanford medical students led by Solomiia Savchuk helped create MIMCloud depository of medical images for TeleHelp Ukraine app providing free medical and mental health support to Ukrainians.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Memorial Sloan Kettering Cancer Center: Elite NCI-designated cancer center with a leading radiation oncology department pioneering IMRT, SBRT, brachytherapy, and proton therapy; comparable as a research-intensive academic radiation oncology program with national referral base.
• MD Anderson Cancer Center: One of the world's largest NCI-designated comprehensive cancer centers with a major radiation oncology program offering proton therapy, brachytherapy, SRS/SBRT, and FLASH research — directly comparable to Stanford in scope, academic stature, and modality breadth.
• Mayo Clinic Radiation Oncology: Multi-site academic radiation oncology program with proton therapy, advanced imaging, and a strong residency program; comparable as an integrated academic practice across multiple geographies with similar technology stack.
• Johns Hopkins Radiation Oncology: Top-tier academic radiation oncology department with proton therapy, brachytherapy, and pioneering FLASH research; comparable in technology leadership, training programs, and translational pipeline.
• UCLA Health Radiation Oncology: Major academic radiation oncology program on the West Coast with proton therapy, brachytherapy, and translational research; Stanford's named partner on recent radiation + immunotherapy sarcoma work and a peer in NCI-funded oncology research.
• Massachusetts General Hospital Radiation Oncology: Harvard-affiliated radiation oncology program with one of the original proton therapy centers in the US, deep research footprint, and ACGME training programs — directly comparable in academic depth and modality coverage.
• Dana-Farber/Brigham and Women's Cancer Center: Harvard-affiliated NCI-designated cancer center with a strong radiation oncology program focused on photon and proton therapy plus translational research; comparable in research output, faculty prestige, and clinical-trial portfolio.

Broad incumbents

• Varian Medical Systems (Siemens Healthineers): Dominant commercial vendor of linear accelerators, treatment planning software (Eclipse), and radiosurgery systems used across academic radiation oncology; a broad incumbent whose equipment, software, and analytics tools underpin much of Stanford's clinical operations.

Others

• Mevion Medical Systems: Manufacturer of compact proton therapy systems and Stanford's technology partner on the ultra-compact proton system; comparable as an adjacent ecosystem participant that supplies the underlying technology Stanford clinically validates.

Regional players

• UCSF Radiation Oncology: Northern California academic radiation oncology program serving overlapping Bay Area geography with comparable clinical, research, and training capabilities; Stanford's most direct regional competitor and collaborator (recent joint sarcoma trial).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/StanfordRadOnc
• YouTubeyoutube.com/@stanfordradiationoncology
• Facebookfacebook.com/stanfordradonc
• LinkedInlinkedin.com/company/stanfordradiationoncology

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stanford Radiation Oncology